Nicolas Reade Harford Simon's Insider Trades & SAST Disclosures
Nicolas Reade Harford Simon's most recent trade in Amicus Therapeutics Inc was a trade of 150,517 Stock Options (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Nicolas Reade Harford Simon.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,517 | 150,517 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 83,073 | 227,427 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.31 per share. | 02 Jan 2025 | 7,482 | 144,354 (0%) | 0% | 9.3 | 69,657 | Common Stock |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.09 per share. | 21 Aug 2024 | 12,529 | 151,836 (0%) | 0% | 12.1 | 151,476 | Common Stock |
| Amicus Therapeutics Inc | Nicolas Reade Simon Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 99,073 | 99,073 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Nicolas Reade Harford Simon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 57,392 | 164,365 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2023 | 189,043 | 189,043 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2023 | 106,973 | 106,973 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges